Esperion Therapeutics (ESPR) Operating Leases (2019 - 2025)
Historic Operating Leases for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $767000.0.
- Esperion Therapeutics' Operating Leases fell 7675.05% to $767000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $767000.0, marking a year-over-year decrease of 7675.05%. This contributed to the annual value of $2.6 million for FY2024, which is 1490.07% down from last year.
- Per Esperion Therapeutics' latest filing, its Operating Leases stood at $767000.0 for Q3 2025, which was down 7675.05% from $1.3 million recorded in Q2 2025.
- Esperion Therapeutics' 5-year Operating Leases high stood at $4.4 million for Q1 2024, and its period low was $47000.0 during Q3 2022.
- Over the past 5 years, Esperion Therapeutics' median Operating Leases value was $1.7 million (recorded in 2023), while the average stood at $1.8 million.
- In the last 5 years, Esperion Therapeutics' Operating Leases plummeted by 9642.04% in 2022 and then soared by 425957.45% in 2023.
- Esperion Therapeutics' Operating Leases (Quarter) stood at $524000.0 in 2021, then increased by 26.91% to $665000.0 in 2022, then soared by 354.14% to $3.0 million in 2023, then fell by 14.9% to $2.6 million in 2024, then plummeted by 70.16% to $767000.0 in 2025.
- Its Operating Leases stands at $767000.0 for Q3 2025, versus $1.3 million for Q2 2025 and $2.0 million for Q1 2025.